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A B S T R A C TObjectives: Numerous factors inﬂuencing medication adherence in
chronically ill patients are well documented, but the paucity of studies
concerning initial treatment course experiences represents a signiﬁ-
cant knowledge gap. As interventions targeting this crucial ﬁrst phase
can affect long-term adherence and outcomes, an international panel
conducted a systematic literature review targeting behavioral or
psychosocial risk factors. Methods: Eligible published articles pre-
senting primary data from 1966 to 2011 were abstracted by independ-
ent reviewers through a validated quality instrument, documenting
terminology, methodological approaches, and factors associated with
initial adherence problems. Results: We identiﬁed 865 potentially
relevant publications; on full review, 24 met eligibility criteria. The
mean Nichol quality score was 47.2 (range 19–74), with excellent
reviewer concordance (0.966, P o 0.01). The most prevalent pharma-
cotherapy terminology was initial, primary, or ﬁrst-ﬁll adherence.
Articles described the following factors commonly associated with
initial nonadherence: patient characteristics (n ¼ 16), medication class
(n ¼ 12), physical comorbidities (n ¼ 12), pharmacy co-payments or
medication costs (n ¼ 12), health beliefs and provider communicationsee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.04.014
thscsa.edu.
ondence to: John E. Zeber, Central Texas Veterans
ple, TX 76502, USA.(n ¼ 5), and other issues. Few studies reported health system factors,
such as pharmacy information, prescribing provider licensure, or
nonpatient dynamics. Conclusions: Several methodological chal-
lenges synthesizing the ﬁndings were observed. Despite implications
for continued medication adherence and clinical outcomes, relatively
few articles directly examined issues associated with initial adher-
ence. Notwithstanding this lack of information, many observed
factors associated with nonadherence are amenable to potential
interventions, establishing a solid foundation for appropriate ongoing
behaviors. Besides clarifying deﬁnitions and methodology, future
research should continue investigating initial prescriptions, treatment
barriers, and organizational efforts to promote better long-term
adherence.
Keywords: behavioral risk factors, ﬁrst ﬁll medication adherence,
initial medication adherence, primary medication adherence,
systematic review.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Medication adherence is deﬁned as “the extent to which a patient
acts in accordance with the prescribed interval and dose of a
dosing regime” [1]. There are two types of medication adherence:
initial adherence, where the patient ﬁlls the medication the ﬁrst
time it is prescribed, and continued adherence, where the patient
continues to reﬁll the medication. Numerous factors pertaining to
poor medication adherence in general for chronically ill patients
are well documented. Although a comprehensive list of potential
inﬂuences would include hundreds of barriers, McHorney [2]
summarized the proximal drivers of self-reported adherence
problems: 1) perceived drug harms versus beneﬁts, 2) the need
for their medication, and 3) out-of-pocket pharmacy costs. Thereexists, however, a paucity of studies concerning experiences
during the very beginning of the treatment course (often referred
to as either “primary, initial, or ﬁrst-ﬁll adherence”), representing
a crucial knowledge gap in understanding why patients choose to
begin taking medication. Accurately determining the rate of
initial adherence is a challenge, because there is currently no
validated, systematic means of determining this process through
existing records. Nevertheless, it was estimated that in a national
study comprising the vast majority of retail pharmacy prescrip-
tions in the United States, the prevalence of new-ﬁll abandon-
ment was 6.3% in 2009, up from 5.1% the prior year [3].
A challenge with evaluating initial adherence stems from an
inability to connect the actions that occur in the prescriber’s
ofﬁce with the patient’s actions outside the ofﬁce. Although thisociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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as electronic systems linking medication prescribers with dis-
pensers more efﬁciently, at present there are few studies that
have attempted to measure initial adherence let alone rigorously
deﬁne it or summarize factors that inﬂuence this issue. In a
survey of more than 9000 patients, the Boston Consulting Group
reported that 18% of the patients did not ﬁll a prescription in the
past 12 months, with 10% giving as a primary reason for non-
adherence that they “can’t get prescription ﬁlled, picked up or
delivered” [4]. Other small, nongeneralizable studies about the
rate of initial adherence do exist, but these are insufﬁcient to
establish a true estimate of the rate of initial nonadherence.
These studies have studied either only speciﬁc conditions such as
asthma [5] or speciﬁc settings such as pharmacies [6]. Further
complicating the picture are the various deﬁnitions used to
describe initial medication behavior. Initial nonadherence can
be when a patient fails to present a prescription to the pharmacy
after it has been ﬁrst ordered by the health care provider, or
neglects to claim a prescription after it has been ﬁlled by the
pharmacist.
Initiating a medication regimen (i.e., initial adherence) may be
the beginning of a complex series of behavior changes that can
have a long-term effect on a patient’s health and well-being.
Therefore, understanding factors that inﬂuence this initial
behavior can enable the clinician and the health system to
identify targeted interventions at this crucial stage in the treat-
ment process to improve the patient’s adherence behaviors and
longer term outcomes. To that end, the Medication Adherence
and Persistence working group of the International Society of
Pharmacoeconomics and Outcomes Research undertook this
systematic review of the literature to identify the current state
of research in this area. The aims of this analysis were to
summarize the current body of literature focused on how
researchers are currently using terminology for initial medication
adherence (and internal consistency within their studies), iden-
tify the research strengths and gaps, document potential behav-
ioral or psychosocial risk factors associated with poor adherence
during this early treatment phase, and offer recommendations
for further research in this area.Methods
An international panel of researchers with considerable expertise
in medication adherence began the process of selecting relevant
articles by conducting a comprehensive, systematic review of the
published literature, and then documented risk factors related to
initial nonadherence. This literature search spanned multiple
databases covering the period from 1966 through July 2012 and
included Medline (PubMed, Ovid), the Cochrane Library, PsycInfo,
Scopus, Web of Science, Embase, and CINAHL. The following
standardized search terms were used, all in conjunction with
and without the term medication, along with “treatment,” “phar-
macy,” and “prescriptions”: primary, initial (non)adherence, pri-
mary, initial (non)compliance, and ﬁrst ﬁll adherence/compliance,
In addition to the general term of “risk factor,” these key terms
were cross-referenced with a lengthy list of potential factors
documented to be associated with poor adherence, or conversely,
better adherence. These included items such as patient character-
istics, medication beliefs, cost, and number of health conditions or
comorbidities. Given the multitude of possible key terms and
related concepts, please refer to the Appendix in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2013.04.014 for
additional details concerning our search terms and overall
strategy. We also iteratively searched the bibliographies of
included articles as well as relevant review articles for additional
eligible publications; this follow-up effort yielded approximately20 potentially new articles, but none that met ﬁnal inclusion
criteria.
Limiting the selection to English publications, we required
that the studies conducted work on primary data analysis, with
additional exclusions made for case series with fewer than 10
patients, or articles presenting conceptual or theoretical work. To
restrict our focus on a limited deﬁnition of initial adherence as
deﬁned by the study authors, further discussions and a complete
review of articles led to excluding those dealing with adherence
during the early treatment course or longitudinal persistence,
rather than factors associated with the very ﬁrst prescription.
These criteria were applied during the review of the article titles,
key words, our initial review of abstracts, and during the
thorough full-text review.
Articles meeting ﬁnal eligibility requirements were then
assessed by two independent reviewers through a validated
quality instrument documenting methodological details; the
Nichol tool evaluates multiple dimensions of research quality,
including study design, how disease conditions were deﬁned, and
descriptions of adherence measurement [7]. Scaled scores are
assigned to a range from 0 to 100, and we report the mean and
variance for all included articles. Each article was then fully
extracted by at least two independent reviewers to document
information concerning adherence deﬁnitions (e.g., primary,
initial, and other), study type (randomized controlled trial, obser-
vational, prospective), the pharmacy data collection method
(ordered prescriptions vs. ﬁlled claims, or patient self-report),
methodology concerning adherence measurement (e.g., number
of ﬁlls within 90 days, medication possession ratio [MPR], and
other techniques), acute and/or chronic disease state and speciﬁc
diagnoses, and therapeutic drug class. Additional information
was collected on patient demographics (including race/culture,
socioeconomic status [SES], health literacy), practitioner type
(primary care, specialist, nurse practitioner, etc.), prescribing
system (electronic, paper), location of dispensing pharmacy
(HMO, chain, community), and patient insurance type and/or
pharmacy co-payments. Finally, as the primary outcome of
interest for this review, signiﬁcant factors affecting initial adher-
ence were summarized, based on the statistically signiﬁcant
results as reported by the study authors, along with observations
concerning study limitations.
After the comprehensive data extractions were completed and
new searches revealed no further included articles, the study
team again reviewed and summarized these data to conﬁrm a
ﬁnal inclusion list, discuss terminology and central themes, and
resolve potential conﬂicts between reviewers. We also present
the most prevalent factors examined in these studies and the
reported association with nonadherence, and summarize relative
effect sizes determined by the authors. Because relatively few
articles also examined the association between initial adherence
and other clinical outcomes, these are noted as a secondary aim
with further discussion of this implication of medication
behavior.Results
Search Results
Overall, the search identiﬁed 865 potentially relevant articles, of
which 307 abstracts were deemed eligible for review of additional
details. The most common exclusion reason by far was an
obvious lack of focus on initial adherence (n ¼ 198), despite
implying such an objective in the publication title or key words.
Other exclusions included articles not analyzing unique primary
data [8], smaller case series [9], conceptual or theoretical articles
[10], and non-English articles [3]. Therefore, only 63 articles were
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determine ﬁnal inclusion. Of these, articles were then further
eliminated where the authors used terminology for initial adher-
ence broadly documenting treatment adherence, longitudinal
persistence, or discontinuation ranging from 1 month to 2 years
after the ﬁrst prescription. This task required a comprehensive
review of study methodology and team member consensus to
conﬁrm a focus on initial adherence. Thus, only 24 articles made
our ﬁnal inclusion list. With the study design ﬂowchart depicted
in Figure 1, these selected publications were then fully extracted
and evaluated per the aforementioned description. Table 1
presents a summary of the ﬁnal included articles. In terms of
the assessed quality, the mean Nichol score for these articles was
47.2  14.2, with a range between 18.5 and 74.1. Both reviewers
closely agreed in their evaluations with an interclass correlation
coefﬁcient for the total score of 0.966 (95% conﬁdence interval
0.948–0.974; P o 0.01).
None of the 24 studies was a randomized trial, and few
presented ﬁndings from prospective study designs; two were
conducted from the prescriber ofﬁces and prescription data
[10,11], and four used prospective data collection by patient
survey [9,20,30,31]. Most articles, however, relied on observational
or retrospective examinations of secondary pharmacy data sets.
Two studies supplemented their analyses with either telephone
interviews [12] or a large number of survey responses [16] to
query patient reasons concerning initial nonadherence. Although
a third of the analyses examined medications for acute condi-
tions, most covered chronic health conditions over a wide range
of physical and psychiatric disorders or drug classes, including
hypertension, diabetes, cardiovascular disease, depression or
anxiety, asthma, osteoporosis, epilepsy, cancer, and multiple
sclerosis. Few articles provided details concerning the speciﬁc
prescriber (physician, nurse practitioner, other), information
about the pharmacy system (e.g., electronic scripts, mailed ﬁlls),
or whether the dispensing pharmacy was part of the health
system or a community pharmacy. No studies describedPotenally relevant publicaons
indenﬁed by search terms 
N = 865
Excluded following review of 
tle and key words N = 558
Publicaons reviewed in full N = 63
further exclusions
• no primary data (3)
• did not examine
Primary or Inial
Adherence (36) 
Final eligible arcles N = 24
Excluded by inial review and 
discussion of abstracts N = 243
Fig. 1 – Study design and systematic review ﬂow chart.organizational or other nonpatient factors associated with initial
adherence.
Study Populations
Cohort size varied greatly across the studies, ranging from 60
patients [10] to extremely large populations of 5.2 million [25],
covering a few hundred to over 10 million total prescriptions
[25,27]. In terms of demographic characteristics (weighted by
individual study sample size), the majority of participants in
these studies were female (average 55%, range 32%–62%), while
the mean patient age in the 16 articles providing data was 56.2
years (range 15–81þ). Fourteen studies were conducted on pre-
dominantly Caucasian populations including three Scandinavian
studies, although the primary language spoken was not clariﬁed.
Eight publications did not report racial/ethnic demographics, and
participants’ SES was not reported in 13 studies. However, six
studies were conducted on individuals with relatively higher
incomes (e.g., 4US $50,000 annually). Five studies included
predominantly lower socioeconomic groups, whereas three stud-
ies reported smaller proportions in this social stratum. The
speciﬁc type of health insurance was not stated in seven articles.
When documented, health insurance beneﬁts primarily consisted
of pharmacy co-payment systems decreasing with total expendi-
tures. Two studies included fully insured participants, while
others described combinations of insurance systems speciﬁc to
that country. Health literacy was not directly examined in any of
the articles, though six studies reported limited evidence of
educational levels; one article reported 25% participants with
some college [14], though the others noted approximately 20%
without a high school diploma.
Medication Adherence: Frequently Used Terminology and
Methodology
With considerable overlap of deﬁnitions, the most prevalent
adherence terminology was primary, used in 46% (11 of 24) of
the eligible publications. Initial was the second most commonly
used term, observed in 42% [20] of the eligible publications,
followed by ﬁrst-ﬁll adherence in 38% [10] of the ﬁnal articles.
The term “early adherence” was seen only once in the included
publications, used in addition with another deﬁnition, along with
a variety of other infrequent terms including new or ﬁrst
prescription, treatment initiation, and index ﬁll. Conducting an
updated search on these additional terms did not reveal further
articles. Three studies examining prescription abandonment,
deﬁned as a patient not picking up a prescription presented at
the pharmacy, were included in the ﬁnal list because these
articles also used another initial adherence term and appeared
to frame their studies in that context [14,25,28]. From the 63
original articles thoroughly reviewed, 39 were excluded because it
was clear that they did not examine the very ﬁrst prescription.
Instead, these articles presented adherence over a period cover-
ing the early treatment course, ranging from a month to 2 years
following the index prescription. Thus, although the key words
and abstracts asserted that these studies targeted initial adher-
ence, the methodology indicated that they were not appropriate
for our working deﬁnition.
Adherence Measurement
In contrast to our objective of focusing on initial adherence, it
became clear that despite using the aforementioned terms to
denote initial adherence and noting this fact in “Methods”
sections, authors frequently meant that initial adherence was
the length of time from the ﬁrst prescription until it was ﬁlled,
although this period varied and alternatives approaches were
observed. The most prevalent time frame was having a
Table 1 – Final list of primary adherence publications meeting inclusion criteria (n ¼ 24).
Primary adherence Reported rate of poor Key risk factors forStudy Study site/population Total sample size† Drug class/condition(s)
deﬁnition adherence‡ nonadherence§
Beardon et al. [11] Scotland 4,854 patients 20,291 Rx Multiple (e.g.,
gastrointestinal,
cardiovascular,
respiratory,
infections, eye,
musculoskeletal)
Primary
noncompliance/
nonredemption
Patients ¼ 14.5%,
Rx ¼ 5.2%
Demographics, cost,
weekend Rx, trainee
MD, drug class
Ekedahl and
Manson [12]
Sweden 89,533 Rx Multiple (e.g.,
cardiovascular,
urinary tract,
antibiotics,
respiratory)
Primary or initial
noncompliance/
nonredemption
Rx ¼ 2.4% Demographics, drug
class, cost,
medication beliefs, RX
incorrect
Fischer et al. [13] United States
(Massachusetts)
75,589 patients 195,930 Rx Multiple (e.g.,
antihypertensives,
antimicrobials, lipid-
lowering agents,
antidepressants, pain
medications)
Primary nonadherence Patients ¼ 22.5%, Rx ¼
28.3%
Demographics, drug
class, provider
specialty/
characteristics
Gleason et al. [14] Ontario, Canada 10,104 patients Tumor necrosis factor
blocker or multiple
sclerosis agent
Prescription
abandonment
Patients ¼ 4.7%–28.5% Cost, drug class
Jackevicius et al.
[15]
United States 4,591 patients 12,832 Rx Multiple (e.g., ACE
inhibitors, beta
blockers, calcium
channel blockers,
lipid-lowering agents,
nitrates, statins)
Primary or initial
nonadherence
Patients ¼ 26%, Rx ¼
21.4%– 27%
Demographics, drug
class, provider type,
discharge counseling,
number of
medications
Karter et al. [16] United States
(California)
27,329 patients, 49,428 Rx Hypoglycemics, lipid-
lowering agents,
antihypertensives,
Primary nonadherence Patients ¼ 4.7%– 41.5% Cost, drug class, poor
treatment response
Kessler et al. [17] United States 636,174 patients, 4.74m Rx Multiple (e.g., asthma,
heart failure,
depression, diabetes,
epilepsy,
hypertension, rhinitis)
Initial prescription or
co-pay,
discontinuation
Wide range across
conditions via
survival analysis
Drug class, cost
Ko et al. [18] Ontario, Canada 11,344 patients Thienopyridine therapy Primary nonadherence,
compliance, initial
prescription, early
discontinuation or
persistence
Patients ¼ 6.9%– 7.1% Demographics, prior
serious condition
Kretzer et al. [19] United States (Hawaii) 28,073 patients Hypertension, diabetes,
congestive heart
failure
First-ﬁll adherence,
initial prescriptions
45%, wide range across
drug class
Drug class
Menckeberg et al.
[20]
The Netherlands 667 patients Inhaled corticosteroids Early discontinuation,
persistence
Patients ¼ 42.4% Treatment response,
side effects,
symptoms
Raebel et al. [21] United States (Colorado) 15,147 patients Diabetes, hypertension,
hyperlipidemia
Primary nonadherence,
initial prescription,
early nonpersistence
Patients ¼ 7.4% Drug class
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Table 1 – continued
Raebel et al. [8] United States (Colorado) 16,173 patients Diabetes, hypertension,
hyperlipidemia
Primary nonadherence,
early nonpersistence
Patients ¼ 7%– 13% Demographics, drug
class, provider type,
smoking, health care
visits
Raue et al. [10] United States (New
York)
60 patients Antidepressants Initial adherence,
treatment initiation
Patients ¼ 13.4% Treatment preferences
Shah et al. [22] United States
(Pennsylvania)
1,132 patients Diabetes (multiple
medications)
First-ﬁll adherence Patients ¼ 15% Drug class, cost,
hemoglobin A1c level
Shah et al. [23] United States
(Pennsylvania)
3,240 patients Hypertension (multiple
medications)
First-ﬁll adherence Patients ¼ 17% Demographics, drug
class, cost, illness
severity
Shrank et al. [24] United States (Colorado,
Nevada)
6,755 patients, 7,532 Rx Oral contraceptives,
calcium channel
blockers, ACE
inhibitors,
angiotensin receptor
blockers, statins,
inhaled
corticosteroids
Index or initial
prescription
Wide range across drug
class
Demographics, co-pays,
drug class,
preferences
Shrank et al. [25] United States 5.25 million patients,
10.35 million Rx
Multiple (e.g., opiates,
antidepressants, oral
hypoglycemics,
insulin, antiepileptics)
Prescription
abandonment, index
or initial prescription
Rx ¼ 3.3% Demographics, drug
class, number of
conditions, cost,
insurance type,
electronic Rx
Solomon et al. [26] United States 17,183 patients Hypertension, diabetes,
or
hypercholesterole
mia
Initiation of therapy or
prescription
Wide range across
conditions via
survival analysis
Co-pays, drug class,
prior Rx experiences
Storm et al. [27] Denmark 322 patients 390 Rx Psoriasis, eczema, acne,
infections (multiple
dermatological
agents)
Primary nonadherence,
initial prescriptions
Patients ¼ 30.7% Demographics, drug
class, provider type,
emergency room Rx
Streeter et al. [28] United States 10,508 patients Oral oncolytics Prescription
abandonment
Patients ¼ 10% Demographics, drug
class, cost, insurance
type, number of
medications
van Geffen et al.
[29]
The Netherlands 965 patients Antidepressants Initiation of therapy,
persistence
Patients ¼ 4.2% Demographics, lack of
diagnosis
Wamala et al. [30] Sweden 31,794 patients Not speciﬁed Primary nonadherence Patients ¼ 4%–11% Demographics, health
beliefs/trust
Wroth and
Pathman [31]
United States
(southwest)
3,926 patients Not speciﬁed Primary nonadherence Patients ¼ 21.6% Demographics, health
status, beliefs/trust
Yood et al. [9] United States
(Massachusetts)
465 patients Bisphosphonate,
calcitonin, raloxifen
Treatment initiation Patients ¼ 42.8% Health beliefs/trust,
alcohol use
ACE, angiotensin-converting enzyme.
 If speciﬁc US states or regions were documented, these are noted; otherwise, US refers to nationally extracted data sets.
† Numbers refer to new prescriptions only.
‡ Poor adherence as deﬁned by the respective study deﬁnition; rates differ across drug classes, other variables examined.
§ Summary list of statistically signiﬁcant variables documented by the study authors.
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V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 9 1 – 9 0 0896dichotomous ﬁll (any vs. none) within 30 days of the initial
prescription [8,21–23,25,27,29], although 2 to 3 months was also
common [9–11,14,16,28]; longer periods were also used several
times, including 4 to 7 months [12,15], and even up to a year
[13,31]. Survival analyses were conducted twice to examine time
until a ﬁll ranging from the ﬁrst 2 months [17] to 5 years [26]; the
ﬁrst study used a multivariable discrete-time period approach,
while the latter used both Kaplan-Meier and Com proportional
hazard models. Notwithstanding, however, the terminology for
initial adherence, suggesting a distinct ﬁrst prescription, a
broader perspective or use of multiple outcomes was occasionally
noted, further complicating our analysis. For example, the MPR
greater than 80% over a 1-year period deﬁned adherence persis-
tence for Ko et al. [18], yet the authors also examined a 14-day
prescription delay following the receipt of a coronary stent.
Similarly, Kretzer et al. [19] used a combination of MPR, gaps, or
switches from an initial drug during 1 year. In other studies,
reasons for both initiating and discontinuing medications during
a 6-month period were examined [20], as was the proportion of
days covered (PDC, comparable to MPR) for patients initiating
treatment along with prescription switches [24]. Finally, Wamala
et al. [30] documented self-reported prescription failure within 90
days, yet it was unclear whether these were restricted to initial
treatment or any ﬁlls.
Prevalence of Poor Adherence
Based on each study deﬁnition, we summarized reported rates of
initial nonadherence. Of the 20 articles with the clearest deﬁni-
tions (i.e., single outcome, no initial prescription within a ﬁnite
number of months), these rates varied between 2.3% and 50%.
Recognizing the large sample size differences between 60 and
over 5 million, the weighted average was 5.1%  1.3%. When
studies reported the total number of prescriptions (n ¼ 6), poor
adherence ranged between 2% and 50%. A more complex sum-
mary of outcomes was observed in four articles with longer
observational windows or those looking at multiple drug classes.
For example, Ko et al. [18] found prescription noninitiation rates
of 16% and 7% (1 week and 1 year, respectively) following receipt
of coronary stents; longer term persistence of 16% to 26% at 3 to 6
months was calculated by using the MPR. Kretzer et al. [19] found
that longer term poor adherence ranged between 45% and 80%
depending on drug class, as did Shrank et al. [24] using the PDC
over a year, ﬁnding rates of 21% to 65% across speciﬁc medication
classes. Wamala et al. [30], not distinguishing between initial
versus any ﬁll, found poor adherence rates between 4% and 11%
by drug class.
Factors Associated with Poor Initial Adherence
Turning to the primary outcome of interest, numerous issues
associated with initial adherence were identiﬁed. Table 2
presents a quantitative summary of only the statistically signiﬁ-
cant ﬁndings from across the 24 studies, along with a summary of
the reported strength of association in relation to initial adher-
ence (i.e., odds ratios [ORs]). The most prevalent factor addressed
was observed differences by drug class or speciﬁc medication
(n ¼ 16). While actual rates are difﬁcult to compare because of the
diversity and the sheer number of drugs analyzed, patients
consistently failed to ﬁll prescriptions for several medication
types. Most notably, this included prescriptions for dermatolog-
ical conditions [11,13] and calcium channel blockers [17,23,24],
along with urinary tract or obstetrics medications and oral
contraceptives [11,12,24]. Poor adherence rates were also high in
treatment for infections [11], injectable anticoagulants [15],
loop diuretics [23], antipsychotics [25], and nutritional supple-
ments or cold and allergy medications [15,25]. Conversely, betteradherence rates were observed for angiotensin-converting
enzyme inhibitors [15,23,24], statins [15,24], antibiotics [12,25],
beta blockers [19,23], and opiates [25]. Beardon et al. [11] and
Ekedahl and Mansson [12] documented similar ﬁndings concern-
ing drugs with higher (cardiovascular, generally deﬁned) and
lower adherence rates (respiratory, musculoskeletal). Other psy-
chotropic drugs had mixed ﬁndings, with better adherence for
antianxiety medications [13]; antidepressants had better reported
rates in one study [25] while among the lowest in another article
[15]. In addition to the effect on initial adherence, Karter et al. [16]
also compared three drug classes over a longer time period (i.e.,
outcomes of none or only one ﬁll during a 2-year window),
ﬁnding that high cholesterol prescriptions were ﬁlled at half the
rate of antihypertensive and hyperglycemic drugs. Also examin-
ing two outcomes, any initial ﬁll within 30 days and the 180-day
PDC, Raebel et al. [8,21] noted that diabetes and hyperlipidemia
scripts failed twice as often as hypertensive medications. Shah
et al. [22]. found that oral hypoglycemic medications, biguanide
and sulfonylurea (11% and 14%, respectively), were ﬁlled far more
often than insulin (26%) [22]. Examining eight different oral
oncolytics, Streeter et al. [28] documented poor adherence rates
ranging from 6.2% (capecitabine) to 27.2% (sorafenib). One article
focused on a single drug class, and so no medication comparison
was conducted [29]. While Gleason et al. [14] focused on the role
of co-payments, they brieﬂy explored drug class interactions with
cost, ﬁnding less price sensitivity for multiple sclerosis agents
than for tumor necrosis factor blockers. Storm et al. [27] directed
their analysis to selected health conditions rather than drug
class, though they noticed that diagnoses associated with lowest
initial adherence (e.g., psoriasis and eczema) tended to have
topical drug applications.
A total of 14 articles presented associations between demo-
graphics or other patient characteristics and initial adherence,
notably age; although younger patients were often substantially
less adherent [12,24,25,27,28,31], several articles observed that
middle aged or older patients experienced more difﬁculty with
initial prescriptions [11,13,15,23,29,30]. Not only low SES was
frequently an adherence barrier, primarily income, but also
individuals living alone or with poor social support
[8,15,18,24,25,28,30], although Wroth and Pathman [31] observed
that married patients were 30% more likely to have adherence
problems. Overall, men exhibited signiﬁcantly better adherence
in most articles speciﬁcally reporting on gender [13,24,25,31], yet
worse behavior in another study [12]. Race/ethnicity was less
commonly examined, though minorities generally were less
adherent [8,31]; van Geffen et al. [29] also noted that non-
Western immigrants failed to initiate antidepressant treatment
at higher rates. Patients in rural areas were slightly less likely to
ﬁll ﬁrst prescriptions in one study examining geographic resi-
dency [25].
Broadly considered, illness severity and disease chronicity
were also examined in 14 articles. Factors negatively inﬂuencing
adherence included patients with a greater number of physical
illnesses [25], a higher Charlson comorbidity score [23], experi-
encing a recent acute myocardial infarction or heart failure [18],
frequent health system contacts prior to the initial ﬁll [8], and
having currently elevated hemoglobin A1c or blood pressure
levels [22]. In addition, patients having chronic conditions such
as diabetes [13] or, for example, psoriasis rather than an acute
skin infection [27], individuals lacking current serious symptoms
such as asthma exacerbations or severe coughing [20], and
patients self-reporting either long-term illnesses or fair to poor
overall health status [30,31] tend to display worse initial adher-
ence behavior. Kessler et al. [17] explored the interaction between
pharmacy co-payments and 10 different diagnoses, observing
that asthma and rhinitis prescriptions were most sensitive to
medication cost while diabetes, epilepsy, and hypertension drugs
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 9 1 – 9 0 0 897were least affected. Similarly, while concentrating on pharmacy
naive patients and medication costs, Solomon et al. [26] found
that higher co-payments led to sharper declines in reﬁlls for
hypertension and high cholesterol drugs (27% and 29%, respec-
tively) than for diabetes medications (11% drop). Examining
perhaps another proxy for illness burden, the number of medi-
cations taken by a patient was positively related to lower
adherence, such as a greater quantity prior to a myocardial
infarction as described by Jackevicius et al. [15], or for oral
oncology adherence in general [28]. Raebel et al. [8], however,
found that patients receiving ﬁlls in multiple drug classes
actually experienced better adherence initially.
Pharmacy co-payments or out-of-pocket medication ex-
penses, reported in 11 articles, represented perhaps the strongest
association with poor initial adherence in terms of effect size or
ORs (see below and Table 2). Although two studies observed no or
minimal adherence differences by co-payment status [8,16],
others documented a signiﬁcant inﬂuence of medication cost
on initial ﬁll behavior [12]. Gleason et al. [14] reported a strong
linear effect across co-payment levels, ranging from a 5% failed
initiation rate for patients paying less than $100 to over 25% as
cost exceeded $500 for expensive specialty drugs. For oncology
medications, a comparable co-payment range led to a fourfold
adherence difference [28]. Summarizing a detailed analysis by
Kessler et al. [17], the co-payment level was signiﬁcantly asso-
ciated with treatment termination, ranging from 1% to 40% as
out-of-pocket costs increased. First-ﬁll adherence problems were
consistently seen in other studies, rates nearly doubling when
patients faced even $10 co-payments [11,22,23]. The risks were
substantially greater in prescriptions attached to $40 to $50 (ORs
of 3.5–4.5 vs. ﬁlls with no co-payments) [16]. Two additional
studies [24,26] did not directly examine co-payments, instead
analyzing the effects of multitiered pharmacy beneﬁts as a proxy
for medication costs, with similar ﬁndings that patients used
fewer nonpreferred drugs.
Medication beliefs and provider relationships frequently inﬂu-
enced initial adherence behavior. Yood et al. [9] observed that
initial adherence rates for osteoporoses nearly doubled in
patients believing that the medication was effective, along with
understanding that their condition warranted treatment, a ﬁnd-
ing echoed by another study [12]. In a randomized trial, Raue
et al. [10] determined that patients offered treatment strongly
congruent with their preferences and effectiveness beliefs
(whether medication, therapy, or no care) had much better
prescription initiation and 4-month adherence rates. A low sense
of trust in the health care system overall was associated with 3.5
times the likelihood of poor adherence, with older patients
experiencing worse problems [30]. Wroth and Pathman [31] also
found that poor adherence was strongly associated with dimen-
sions of trust and the therapeutic alliance, including lacking
conﬁdence in their doctor’s ability to help them, and low
satisfaction with their quality of care. In addition, Shrank et al.
[25] point out that patients often avoided nonpreferred medica-
tions, another expression of treatment preferences. Also
described to some extent in ﬁve studies, certain physician
characteristics were correlated with lower initial adherence, such
as scripts written by a trainee, junior, or younger physician
[11,13,27]. Prescriptions written by inpatient cardiology special-
ists were ﬁlled more frequently [15], yet outpatient scripts
originating from primary care physicians were ﬁlled more often
than scripts for patients seeing specialist providers [8].
A variety of other factors were found to be associated with
initial adherence. Poor treatment response, reﬂecting either past
patient experience or new prescriptions, was negatively associ-
ated with initial adherence [16,20]; not surprisingly, medication
side effects also reduced the likelihood of adherence, though
directly examined in only one study [20]. A variety of otherfactors associated with initial adherence included electronic
prescriptions less likely to be ﬁlled [25], along with weekend
scripts, those written in error, or sent to an outside pharmacy
[11,12]. Patients receiving discharge medication counseling
tended to initiate treatment more often [15], as were individuals
receiving emergency room prescriptions rather than those from
routine clinic appointments [27]. Diabetic patients who smoked
[8], those prescribed antidepressants without a clear mental
health diagnosis [29], and individuals lacking transportation [31]
were nearly twice as likely to be poorly adherent. Finally, patients
with insurance coverage other than an HMO and those with
shorter coverage periods prior to the initial ﬁll had worse
adherence [8].
Although a statistical meta-analysis falls outside the intended
scope of this study, some information of observed strength of
association on model variables would be informative, rather than
simply the number of times risk factors were examined. As such,
Table 2 also provides a summary of reported effect sizes as
documented by the study authors. Recognizing the large diversity
of adherence deﬁnitions, study designs, populations, and ana-
lytical approaches, signiﬁcant factors included speciﬁc medica-
tion or drug class (OR range 1.50–4.87), the number of disease
conditions or illness severity (ORs 1.40–2.78), and medication cost
or co-payments (ORs 1.20–7.30). In addition, though less fre-
quently examined and demonstrating somewhat inconsistent
effects, lower SES had up to a sixfold association with poor
adherence (OR ¼ 6.2), along with other inﬂuential factors includ-
ing medication beliefs and patient characteristics such as race/
ethnicity and age.Discussion
Although initial adherence and associated factors represent a
critical issue, relatively little high-quality work has been con-
ducted targeting this very ﬁrst treatment phase. Our systematic
review revealed only 24 articles covering a period of two decades,
representing six different countries and diverse populations.
Many studies were of variable methodological quality, docu-
mented a range of cohort sizes, and often contained an insufﬁ-
cient description or choice of adherence measures. While a
detailed assessment of the methodology and statistical analysis
of these articles was not the primary objective, we endeavored to
restrict inclusion to articles focused on initial adherence as
deﬁned by the study authors. We observed signiﬁcant overlap
with “early” adherence, which in some cases extended to nearly 1
year. Many ineligible articles implied that the goal was “primary
or initial” adherence, and used other key words such as non-
redemption, discontinuation, or abandonment, which caused
additional confusion. Thus, analysis of initial medication adher-
ence and comparisons between studies can be misleading with-
out careful consideration of the deﬁnition posed. The fact that
similar terminology was used for strikingly different methodo-
logical approaches is telling, and suggests that much founda-
tional work is required before a solid working deﬁnition of initial
adherence is formalized.
Summarizing ﬁndings from our central aim, numerous behav-
ioral, psychosocial, and other risk factors were associated with
initial nonadherence. These included speciﬁc medication type,
patient characteristics, comorbidities or illness severity, drug
costs, medication beliefs and provider relationships, and a variety
of other signiﬁcant factors. While some articles focused on a
single issue, for example, drug class [21] or pharmacy co-
payments [17], most studies covered several factors and their
contribution to adherence. Not surprisingly, many of the same
issues are frequently documented in connection with general
adherence, such as common drug classes [32,33], differential
Table 2 – Risk factors frequently associated with poor initial medication adherence.
Risk factors Number of
times reported
Reported effect size (range of
odds ratios/relative risks)
References
Drug class/speciﬁc medication 16 1.5–4.87* [8,11–17,19,21–25,27,28]
Demographics/patient characteristics 14
Age (younger) 12 1.10 – 2.70† [11–13,15,24,25,27–31]
Socioeconomic status (lower) 8 0.32–6.20‡ [8,15,18,24,25,28,30,31]
Gender (male) 5 0.96–1.36§ [12,13,24,25,31]
Race/ethnicity (non-White) 3 1.60–1.74 [8,29,31]
Urban residency 1 1.08 [25]
Medical comorbidities, illness severity, and
disease chronicity
14 1.40–2.78 [8,13,15,17,18,20,22,23,25–
28,30,31]
Pharmacy co-payments/out-of-pocket
medication expenses
11 1.20–7.3|| [11,12,14,16,17,22–26,28]
Medication beliefs or provider relationships 6 1.40–1.85 [9,10,12,24,30,31]
Physician characteristics (e.g., junior,
resident, primary care vs. specialist)
5 1.10–1.51 [8,11,13,15,27]
Treatment response/side effects 2 NA¶ [16,20]
Miscellaneous risk factors
Electronic prescriptions 1.34 [25]
Weekend scripts/errors/outside pharmacy 1.22–1.55 [11,12]
Discharge medication counseling 1.61 [15]
Prescription from emergency Room 1.15 [27]
Tobacco use 1.63 [8]
Antidepressants without mental health DX 2.70 [29]
Patients lacking transportation 1.80 [31]
Non-HMO insurance plan 2.56 [8]
Shorter insurance coverage period 1.24 [8]
NA, not applicable/available; OR, odds ratio; SES, socioeconomic status.
 Difﬁcult variable to summarize given well over 50 different medications or drug classes examined in these studies. Above OR range reﬂects
only those associated with nonadherence (many drugs also had strong positive, beneﬁcial relationships).
† While most studies found about a twofold higher risk of nonadherence in younger patients, one exception was initial antidepressant ﬁlls,
where van Geffen et al. [29] reported an 80% higher risk in patients older than 60 y.
‡ A tremendous range was noted for effect of SES/income, as reported coefﬁcients varied greatly by age group, gender, and other study
variables; several of these eight articles reported multiple values with consistent negative association with adherence. Most studies observed
a 30% to 50%þ higher risk of nonadherence for patients with lower SES; conversely, Ko et al. [18] and Jackevicius et al. [15] found that low-
income Canadian patients who were entitled to pharmacy assistance were much less likely to not ﬁll initial prescriptions.
§ Fischer et al. [13] and Shrank et al. [24] found that men had slightly better adherence, while the other three studies documented about a 30%
better adherence rate in women.
 Signiﬁcant variability was presented in both self-reported and researcher-deﬁned health status or severity of illness, and in study design
(survey, qualitative interviews, secondary data analysis).
∥ A variety of medication co-payment and out-of-pocket cost levels were examined, contributing to a wide range of ﬁndings for this factor as
well. ORs of 2.0 and above were reported for co-payments of $10 or more and over 4.0 for co-payments of $30 or more.
¶ Neither the Menckeberg et al. article [20] nor the Karter et al. [16] article provided a direct comparative value for this factor and
nonadherence. The former study provided only a descriptive prevalence of poor initial adherence on side effects per patient report, while
Karter et al. [16] presented the association of nonadherence by treatment response expressed through a range of continuous diabetic
outcomes.
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health beliefs [37,38], or the detrimental effect of medication cost
[39,40]. Realizing that the mere prevalence of variables examined
does not equate to strength of inﬂuence, we did ﬁnd that certain
factors had a much greater effect on poor adherence, including
medication type, health status or comorbidities, and patient
demographics. Further work is needed to help quantitate the
relative role of numerous variables on initial medication
behavior.
Yet practically speaking, some factors might assume even
greater inﬂuence over adherence and later outcomes at the begin-
ning of treatment. For example, although direct personal exposure
to ﬁrst prescriptions cannot perfectly inform future adverse reac-
tions or potential treatment response, patients provided sufﬁcient
educational information about their medication (beneﬁts, sideeffects, instructions) during the clinical encounter are more likely
to experience better adherence [41–43]. Similarly, addressing beliefs
about medication efﬁcacy before pharmacotherapy commences
increases ﬁrst-ﬁll behavior [44], supporting growing evidence that
an existing solid therapeutic alliance can greatly improve adher-
ence [45–47]. Empirical ﬁndings in our review concerning medica-
tion cost suggest that economic considerations and potential
“sticker shock” effects impact initial adherence behavior
[14,16,17,22–26,28,]. Plus, as Shrank et al. [25] pointed out, new users
of a speciﬁc medication are less likely to ﬁll initial prescriptions,
representing a crucial opportunity to provide additional information
or address concerns. Although many interventions successfully
target adherence during all phases of treatment, these are often
not cost-effective [48]; however, some relatively simple efforts such
as a pharmacy-based telephone call to conﬁrm prescription receipt
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ence [49]. Such organizational interventions introduced at the
commencement of treatment rather than later can yield substantial
beneﬁts. Out-of-pocket costs are difﬁcult to address, yet individuals
perceiving that their treatment is more patient-centered do expe-
rience lower cost-related adherence problems [50].
Unlike numerous studies associating poor adherence in gen-
eral to negative ramiﬁcations, only a few of these publications
linked initial nonadherence to clinical outcomes. Jackevicius
et al. [15] noted higher mortality in patients receiving fewer
initial prescriptions, while Ko et al. [18] observed similar ﬁndings
for thienopyridine ﬁlls following coronary events. In the two
Shah et al. [22,23] studies, patients appropriately ﬁlling index
prescriptions had a threefold reduction in hemoglobin A1c levels
and signiﬁcantly lower blood pressure readings versus nonadher-
ent individuals. Because the majority of the 24 studies involved
analyses of retrospective databases, it is possible that clinical
outcomes data were not available.
Although the Nichol quality assessment tool evaluates several
key study facets [7], including terminology and cohort speciﬁca-
tion, it might not perfectly capture all quality dimensions and
study design limitations. Perhaps signiﬁcantly, only ﬁve studies
reported model ﬁt or predictive ability concerning initial adher-
ence; with one exception [10], the authors acknowledged a “poor
ability to explain adherence” [8], modest at best c-statistics
[14,18], and low r2 values [28]. Yet these ﬁndings are comparable
to many studies of cross-sectional or longer term adherence
[51,52]. Furthermore, few studies [9,10,12,20,30,31] directly sur-
veyed patients to solicit reasons for prescription failure, instead
offering descriptive studies of pharmacy data sets. Administra-
tive records provide essential information to begin recognizing
patients at higher risk for initial adherence problems, but a
comprehensive examination surrounding behaviors extends past
documenting many of the variables available in this limited set of
articles. In addition to methodological advancements, the ﬁeld
needs to move beyond simply listing statistically signiﬁcant
factors associated with adherence and rapidly transition toward
a deeper understanding of the rationale underlying these
ﬁndings.
Study limitations begin with a relatively small sample of
relevant articles, despite thorough efforts to uncover publications
addressing initial adherence. The aforementioned methodolog-
ical issue deﬁning initial adherence signiﬁes not only a potential
problem for included articles but also summarizing and trans-
lating our ﬁndings within a consistent framework. By extension,
longitudinal patient medication experiences and associated fac-
tors following initial prescriptions were not examined; ongoing
work must continue to reﬁne and evaluate study design
approaches and inﬂuences on adherence over time for chronic
conditions. Only publications in English were eligible for this
review, and we did not cover discussions surrounding theoretical
issues or conceptual frameworks, nor studies presenting qual-
itative research objectives. Finally, the fact that several addi-
tional, potential relevant articles were revealed in our iterative
search raises additional questions about the need for more rigid
operational deﬁnitions of initial adherence, the use of appropri-
ate key words, and how such issues should guide future research
inquiries. Nevertheless, this synthesis of currently available
information addresses a knowledge gap to stimulate and struc-
ture further research efforts.
This systematic review demonstrates that initial adherence is a
complex phenomenon regarding deﬁnitional aspects and factors
affecting its occurrence. In addition to clinical challenges surround-
ing initial treatment decisions, researchers and policymakers must
understand potential inconsistencies in terminology and methodo-
logical approaches when evaluating the current state of the
literature. Recognizing the strengths of many studies into initialadherence, we must also acknowledge inherent limitations about
principle ﬁndings, translating existing work to improve patient care,
and shaping future investigations. Initial recommendations for our
working group would include a deeper inquiry into study method-
ology, required to truly distinguish initial adherence from a broader
deﬁnition of early adherence periods and how this affects inter-
pretation of ﬁndings. A much more careful review and codiﬁcation
of the term “initial or primary adherence” should be established to
allow comparison of ﬁndings across studies. Further research
should also address additional psychosocial and ﬁnancial consid-
erations for why patients are nonadherent, interventions targeting
medication beliefs, patient-centered treatment approaches and the
therapeutic alliance, physician or health system factors, and inter-
actions of issues that represent barriers to appropriate adherence
behavior. This should entail a more rigorous methodological review
of the strength of association between risk factors and nonadher-
ence, such as a true meta-analysis approach, after more stand-
ardized terminology has been established. Finally, studies
examining the association between initial adherence and longitu-
dinal patient outcomes are essential in highlighting the importance
of this evolving research.
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